delta-Aminolevulinate dehydratase activity and oxidative stress during melphalan and cyclophosphamide-BCNU-etoposide (CBV) conditioning regimens in autologous bone marrow transplantation patients.
Severe toxicity is associated with cytotoxic drugs used during the conditioning regimen (CR) preceding bone marrow transplantation (BMT). The aim of this study was to evaluate the involvement of oxidative stress and possible use of delta-aminolevulinate dehydratase (delta-ALA-D) activity as a marker of oxidative stress in autologous BMT patients. We have also compared common drugs that are used during CR, namely, melphalan (M-200) and cyclophosphamide-BCNU-etoposide (CBV), in order to determine whether either of them could be less toxic to patients in terms of oxidative stress. The sample consisted of 10 patients admitted for autologous BMT, 5 with M-200 CR and 5 with CBV CR and 10 healthy controls. Lipid peroxidation (estimated as thiobarbituric acid-reactive substances, TBARS), vitamin C, thiol levels, catalase, superoxide dismutase and delta-ALA-D activity were determined before CR, during CR and on days 10 and 20 after BMT. Signs of exacerbated oxidative stress were minimal before CR, except for the CVB group (patients with lymphoma) where an increase in TBARS and a decrease in P-SH were detected. Indices of oxidative stress changed in both groups (CBV and M-200) during CR and up to 20 days after BMT. There was a decrease in enzymatic and non-enzymatic antioxidant defenses and in delta-ALA-D activity and an increase in lipoperoxidation in the blood of both patient groups. In conclusion, CBV and, principally, M-200 caused oxidative stress in patients undergoing autologous BMT and blood delta-ALA-D activity seems to be an additional biomarker of oxidative stress in BMT patients.
Gonçalves
Thissiane L
TL
Departamento de Química, CCNE, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil. thissianegonvalves@yahoo.com.br
Benvegnú
Dalila M
DM
Bonfanti
Gabriela
G
Frediani
Andressa V
AV
Rocha
João B T
JB
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001205:Ascorbic Acid / Q000097:blood; D015415:Biomarkers / Q000032:analysis; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002330:Carmustine / Q000009:adverse effects; D016022:Case-Control Studies; D003520:Cyclophosphamide / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008558:Melphalan / Q000009:adverse effects*; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D000623:Porphobilinogen Synthase / Q000097:blood*; D017382:Reactive Oxygen Species / Q000097:blood; D013438:Sulfhydryl Compounds / Q000097:blood; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014182:Transplantation, Autologous
D015415:Biomarkers; D017382:Reactive Oxygen Species; D013438:Sulfhydryl Compounds; D005047:Etoposide; D003520:Cyclophosphamide; D000623:Porphobilinogen Synthase; D001205:Ascorbic Acid; D008558:Melphalan; D002330:Carmustine